Ray E Hershberger1, Michael M Givertz2, Carolyn Y Ho3, Daniel P Judge4, Paul F Kantor5, Kim L McBride6, Ana Morales7, Matthew R G Taylor8, Matteo Vatta9,10,11, Stephanie M Ware10,12. 1. Division of Human Genetics, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. Ray.Hershberger@osumc.edu. 2. Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. 3. Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, USA. 4. Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina, USA. 5. Division of Pediatric Cardiology, University of Alberta and Stollery Children's Hospital, Edmonton, Alberta, Canada. 6. Center for Cardiovascular Research, Nationwide Children's Hospital, and Department of Pediatrics, Ohio State University, Columbus, Ohio, USA. 7. Division of Human Genetics, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. 8. Adult Medical Genetics Program, Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. 9. Invitae Corporation, San Francisco, California, USA. 10. Departments of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA. 11. Departments of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA. 12. Departments of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Abstract
PURPOSE: The purpose of this document is to provide updated guidance for the genetic evaluation of cardiomyopathy and for an approach to manage secondary findings from cardiomyopathy genes. The genetic bases of the primary cardiomyopathies (dilated, hypertrophic, arrhythmogenic right ventricular, and restrictive) have been established, and each is medically actionable; in most cases established treatments or interventions are available to improve survival, reduce morbidity, and enhance quality of life. METHODS: A writing group of cardiologists and genetics professionals updated guidance, first published in 2009 for the Heart Failure Society of America (HFSA), in a collaboration with the American College of Medical Genetics and Genomics (ACMG). Each recommendation was assigned to teams of individuals by expertise, literature was reviewed, and recommendations were decided by consensus of the writing group. Recommendations for family history, phenotype screening of at-risk family members, referral to expert centers as needed, genetic counseling, and cardiovascular therapies, informed in part by phenotype, are presented in the HFSA document. RESULTS: A genetic evaluation of cardiomyopathy is indicated with a cardiomyopathy diagnosis, which includes genetic testing. Guidance is also provided for clinical approaches to secondary findings from cardiomyopathy genes. This is relevant as cardiomyopathy is the phenotype associated with 27% of the genes on the ACMG list for return of secondary findings. Recommendations herein are considered expert opinion per current ACMG policy as no systematic approach to literature review was conducted. CONCLUSION: Genetic testing is indicated for cardiomyopathy to assist in patient care and management of at-risk family members.
PURPOSE: The purpose of this document is to provide updated guidance for the genetic evaluation of cardiomyopathy and for an approach to manage secondary findings from cardiomyopathy genes. The genetic bases of the primary cardiomyopathies (dilated, hypertrophic, arrhythmogenic right ventricular, and restrictive) have been established, and each is medically actionable; in most cases established treatments or interventions are available to improve survival, reduce morbidity, and enhance quality of life. METHODS: A writing group of cardiologists and genetics professionals updated guidance, first published in 2009 for the Heart Failure Society of America (HFSA), in a collaboration with the American College of Medical Genetics and Genomics (ACMG). Each recommendation was assigned to teams of individuals by expertise, literature was reviewed, and recommendations were decided by consensus of the writing group. Recommendations for family history, phenotype screening of at-risk family members, referral to expert centers as needed, genetic counseling, and cardiovascular therapies, informed in part by phenotype, are presented in the HFSA document. RESULTS: A genetic evaluation of cardiomyopathy is indicated with a cardiomyopathy diagnosis, which includes genetic testing. Guidance is also provided for clinical approaches to secondary findings from cardiomyopathy genes. This is relevant as cardiomyopathy is the phenotype associated with 27% of the genes on the ACMG list for return of secondary findings. Recommendations herein are considered expert opinion per current ACMG policy as no systematic approach to literature review was conducted. CONCLUSION: Genetic testing is indicated for cardiomyopathy to assist in patient care and management of at-risk family members.
Entities:
Keywords:
Cardiomyopathy; Genetic analysis; Genetics; Practice resource; Secondary findings
Authors: Ana Morales; Daniel D Kinnamon; Elizabeth Jordan; Julia Platt; Matteo Vatta; Michael O Dorschner; Carl A Starkey; Jonathan O Mead; Tomohiko Ai; Wylie Burke; Julie Gastier-Foster; Gail P Jarvik; Heidi L Rehm; Deborah A Nickerson; Ray E Hershberger Journal: Circ Genom Precis Med Date: 2020-03-11
Authors: Rahul Goli; Jian Li; Jeff Brandimarto; Lisa D Levine; Valerie Riis; Quentin McAfee; Steven DePalma; Alireza Haghighi; J G Seidman; Christine E Seidman; Daniel Jacoby; George Macones; Daniel P Judge; Sarosh Rana; Kenneth B Margulies; Thomas P Cappola; Rami Alharethi; Julie Damp; Eileen Hsich; Uri Elkayam; Richard Sheppard; Jeffrey D Alexis; John Boehmer; Chizuko Kamiya; Finn Gustafsson; Peter Damm; Anne S Ersbøll; Sorel Goland; Denise Hilfiker-Kleiner; Dennis M McNamara; Zolt Arany Journal: Circulation Date: 2021-04-20 Impact factor: 29.690
Authors: Alice Ghidoni; Perry M Elliott; Petros Syrris; Hugh Calkins; Cynthia A James; Daniel P Judge; Brittney Murray; Julien Barc; Vincent Probst; Jean Jacques Schott; Jiang-Ping Song; Richard N W Hauer; Edgar T Hoorntje; J Peter van Tintelen; Eric Schulze-Bahr; Robert M Hamilton; Kirti Mittal; Christopher Semsarian; Elijah R Behr; Michael J Ackerman; Cristina Basso; Gianfranco Parati; Davide Gentilini; Maria-Christina Kotta; Bongani M Mayosi; Peter J Schwartz; Lia Crotti Journal: Circ Genom Precis Med Date: 2021-02-10